Pfizer: extension of indication for RSV vaccine

Published: 2025-04-01 08:36:34 ET PFE

Pfizer announced on Tuesday that the European Commission has approved its bivalent respiratory syncytial virus (RSV) vaccine for the immunization of adults.The vaccine, previously indicated for patients over 60 years of age, can now be prescribed for people aged 18 to 59.RSV is a common respiratory virus that manifests itself with cold-like symptoms, but can be dangerous in more vulnerable populations, particularly who have underlying respiratory or cardiac diseases.The authorization from Brussels - which follows a positive opinion already given by the CHMP - applies to the 27 countries of the European Union, as well as Iceland, Liechtenstein and Norway.Copyright (c) 2025 CercleFinance.com. All rights reserved.